The pharmacokinetics of diclofenac sodium following intravenous and oral administration
- PMID: 527637
- DOI: 10.1007/BF00568201
The pharmacokinetics of diclofenac sodium following intravenous and oral administration
Abstract
The pharmacokinetics of diclofenac were examined following single rapid intravenous injection and also following single oral doses to healthy female volunteers. After intravenous injection plasma levels of diclofenac fell rapidly and were below the limits of detection at 5.5 h postdosing. Individual drug profiles were described by a triexponential function and mean half-lives of the three exponential phases were 0.05, 0.26 and 1.1 h. After oral doses of enteric-coated tablets, the lag time between dosing and the appearance of drug in plasma varied between 1.0 and 4.5 h. However once drug absorption had commenced similar plasma drug profiles were obtained in different individuals. Peak plasma diclofenac levels ranged from 1.4 to 3.0 microgram . ml-1. The mean terminal drug half-life in plasma was 1.8 h after oral doses. This value was not significantly greater than the value of 1.1 h following intravenous doses. Fifty percent of orally dosed diclofenac did not reach the systemic circulation due, predominantly, to first-pass metabolism.
Similar articles
-
A study of the effect of aspirin on the pharmacokinetics of oral and intravenous diclofenac sodium.Eur J Clin Pharmacol. 1980 Nov;18(5):415-8. doi: 10.1007/BF00636795. Eur J Clin Pharmacol. 1980. PMID: 7439264
-
The influence of food on the absorption of diclofenac after single and multiple oral doses.Eur J Clin Pharmacol. 1981 Jan;19(1):33-7. doi: 10.1007/BF00558380. Eur J Clin Pharmacol. 1981. PMID: 7461021
-
The pharmacokinetics of diclofenac sodium in patients with active rheumatoid disease.Eur J Clin Pharmacol. 1982;21(4):331-4. doi: 10.1007/BF00637622. Eur J Clin Pharmacol. 1982. PMID: 7056279
-
Factors affecting the pharmacokinetics of diclofenac sodium (Voltarol).Rheumatol Rehabil. 1979;Suppl 2:38-46. Rheumatol Rehabil. 1979. PMID: 531447
-
Biopharmaceutical profile of diclofenac-misoprostol combination tablet, Arthrotec.Scand J Rheumatol Suppl. 1992;96:37-48. doi: 10.3109/03009749209095098. Scand J Rheumatol Suppl. 1992. PMID: 1439623 Review.
Cited by
-
A risk-benefit appraisal of injectable NSAIDs in the management of postoperative pain.Drug Saf. 1993 Nov;9(5):380-93. doi: 10.2165/00002018-199309050-00006. Drug Saf. 1993. PMID: 8280405 Review.
-
Understanding In Vivo Dissolution of Immediate Release (IR) Solid Oral Drug Products Containing Weak Acid BCS Class 2 (BCS Class 2a) Drugs.AAPS J. 2021 Oct 26;23(6):113. doi: 10.1208/s12248-021-00639-0. AAPS J. 2021. PMID: 34704158
-
Effect of formulation parameters on pharmacokinetics, pharmacodynamics, and safety of diclofenac nanomedicine.Drug Deliv Transl Res. 2019 Oct;9(5):867-878. doi: 10.1007/s13346-018-00614-x. Drug Deliv Transl Res. 2019. PMID: 30903395
-
Human pharmacokinetics of tolfenamic acid, a new anti-inflammatory agent.Eur J Clin Pharmacol. 1981;19(5):359-65. doi: 10.1007/BF00544587. Eur J Clin Pharmacol. 1981. PMID: 7238564
-
Intestinal Metabolism of Diclofenac by Polymorphic UGT2B17 Correlates with its Highly Variable Pharmacokinetics and Safety across Populations.Clin Pharmacol Ther. 2023 Jul;114(1):161-172. doi: 10.1002/cpt.2907. Epub 2023 Apr 29. Clin Pharmacol Ther. 2023. PMID: 37042794 Free PMC article.
References
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources